Galectin Therapeutics (GALT)
2.42
+0.09 (3.86%)
Upcoming Events
Latest Headlines
Form 4 GALECTIN THERAPEUTICS For: May 26 Filed by: Jamil Khurram
May 28, 2026 9:13 AM - SEC Filing
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
May 27, 2026 8:00 AM - Globe NewsWire
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
May 15, 2026 8:00 AM - Globe NewsWire
Form 8-K GALECTIN THERAPEUTICS For: May 15
May 15, 2026 7:51 AM - SEC Filing
Form 10-Q GALECTIN THERAPEUTICS For: Mar 31
May 15, 2026 7:46 AM - SEC Filing
Galectin Therapeutics publishes belapectin trial results in Hepatology
May 11, 2026 8:00 AM - StreetInsider
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
May 11, 2026 8:00 AM - Globe NewsWire
Form EFFECT GALECTIN THERAPEUTICS
April 13, 2026 6:04 AM - SEC Filing
Galectin Therapeutics (GALT) files mixed shelf
March 31, 2026 4:15 PM - StreetInsider
Form S-3 GALECTIN THERAPEUTICS
March 31, 2026 4:12 PM - SEC Filing
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
March 31, 2026 8:01 AM - Globe NewsWire
Form 8-K GALECTIN THERAPEUTICS For: Mar 31
March 31, 2026 7:56 AM - SEC Filing
Form 10-K GALECTIN THERAPEUTICS For: Dec 31
March 31, 2026 7:51 AM - SEC Filing
Form 4 GALECTIN THERAPEUTICS For: Mar 12 Filed by: Brem Henry
March 17, 2026 9:47 AM - SEC Filing
Form 3 GALECTIN THERAPEUTICS For: Mar 12 Filed by: Brem Henry
March 17, 2026 9:47 AM - SEC Filing
Galectin Therapeutics appoints Henry Brem to board of directors
March 17, 2026 8:01 AM - StreetInsider
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D.
March 17, 2026 8:00 AM - Globe NewsWire
Form 8-K GALECTIN THERAPEUTICS For: Mar 12
March 17, 2026 7:50 AM - SEC Filing
Full Article List
